Cost-effectiveness comparison of dalpiciclib and abemaciclib combined with an aromatase inhibitor as first-line treatment for HR+/HER2− advanced breast cancer

  • Published on 03/28/2024
  •  Reading time: 4 min.

Juan Hong a,* , Tujia Chen b,* , Lihui Ouyang c , Ning Du a , Anna Li a , Zhongqi Zhou d , HaiLing Zhang d , Zhengzheng Xia a,* & Jun Meng a,*

a Department of Pharmacy, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital & Shenzhen Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Shenzhen, China
b Department of Pharmacy, Boai Hospital of Zhongshan, Zhongshan, China
c Department of Pharmacy, The Affiliated Changsha Hospital of Xiangya School of Medicine, Central South University, Changsha, China
d School of Pharmacy, Guangdong Medical University, Dongguan, China

CONTACT Zhengzheng Xia mailto:xiazhengzheng@cicams-sz.org.cn
Jun Meng mailto:meng@cicams-sz.org.cn Department of Pharmacy, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital & Shenzhen Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Shenzhen 518116, China

ContentGeneMD

To continue reading this article in Full-Text...

* Access is totally free, without commitment or condition. Service exclusively reserved for healthcare professionals.

Peer-Reviewed Journals A-Z

Search | Advanced search

Get the latest news in Oncology

Receive our newsletter to stay up to date with the latest news in Oncology

More articles

From peer-reviewed journals in Oncology